News Author: Ted Bosworth Publish date: February 24, 2016
Key clinical point: A proof-of-principle study suggests that procedural success with robotic angioplasty is at least as good in patients with acut...
News Author: Ted Bosworth Publish date: February 24, 2016
Key clinical point: If cardiovascular protection with PCSK9 inhibitors meets expectations, treating all 23 million Americans who may be indicated ...
News Author: Ted Bosworth Publish date: February 6, 2016
News Author: Ted Bosworth Publish date: February 3, 2016
Children with autism spectrum disorders may derive benefit from psychotropic therapies but not for core symptoms.
News Author: Ted Bosworth Publish date: February 3, 2016
News Author: Ted Bosworth Publish date: February 3, 2016
News Author: Ted Bosworth Publish date: February 2, 2016
With two new agents added to an already sizable list of long-acting stimulants in the last 4 months, ADHD therapy can be better individualized.
News Author: Ted Bosworth Publish date: January 30, 2016
Key clinical point: In adolescents with both attention-deficit/hyperactivity disorder and substance use disorder, control of substance use comes f...
News Author: Ted Bosworth Publish date: December 15, 2015
A two-drug regimen without ribavirin was found superior to the current standard of care for genotype 2 (GT2) hepatitis C virus infection, according to...
News Author: Ted Bosworth Publish date: November 24, 2015
Key clinical point: Despite a national decline in the prevalence of hepatitis C virus infection, the prevalence of cirrhosis among HCV-infected pa...
News Author: Ted Bosworth Publish date: November 18, 2015
Sustained virologic response in patients with hepatitis C virus infection is associated with large reductions in all-cause mortality and appears to el...
News Author: Ted Bosworth Publish date: November 18, 2015
Sustained virologic response in patients with well controlled hepatic C virus infection does not protect select subgroups of this cohort from liver ca...
News Author: Ted Bosworth Publish date: November 18, 2015
NVR 3-778, an experimental hepatitis B virus core inhibitor, showed substantial activity and was well tolerated in an initial phase Ib study.
News Author: Ted Bosworth Publish date: November 17, 2015
In real-world setting, sofosbuvir in combination with ribavirin (SOF/R) provided meaningful benefits for special populations with hepatitis C virus in...
News Author: Ted Bosworth Publish date: November 17, 2015
Key clinical point: A five-drug antiviral combination appears to be effective for retreatment of patients with hepatitis C virus infection who hav...
